AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 81 min read$ANGO

AngioDynamics, Inc. (ANGO) Appoints Eric Honroth CEO

AngioDynamics, Inc. (ANGO) named Eric Honroth as President and CEO, effective Nov. 2, 2026. He replaces Jim Clemmer, who will leave the board but stay as a consultant. The company aims to advance its transformation and Med Tech momentum under new leadership, according to the press release.

Original reporting
tradingview.com
Published Oct 8, 2026, 10:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 10:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AngioDynamics, Inc. (ANGO) Appoints Eric Honroth CEO — source image
Source · tradingview.com
Decision brief

The 30-second read

$ANGONeutralLow
01

Why it matters

The change is a primary corporate event but lacks quantitative guidance, limiting immediate trade signals.

02

Market read

Executive change may influence AngioDynamics' strategic execution and stock perception.

03

What to watch

No disclosed compensation details or strategic plan specifics yet.

Relevance 7/10Novelty 6/10Timing: effective Nov 2, 2026

Background

Press release from BusinessWire announcing the CEO transition.

Company-level read

Ticker impact

$ANGONeutralMedium confidence
Context

AngioDynamics announced Eric Honroth will become President and CEO effective Nov. 2, 2026, replacing Jim Clemmer.

Expected impact

potential modest upside as market prices in new CEO outlook

Evidence & confidence

New CEO appointments often lead to short‑term price moves, but impact depends on execution of the transformation plan.

Market effects

Sector

May signal continued momentum in the med‑tech sector as AngioDynamics pushes its transformation.

Regional

U.S. biotech/med‑tech investors may adjust exposure.

Global

Limited to investors tracking U.S. med‑tech equities.

Counterpoint

What could challenge this read

The appointment could be a distraction; execution risk remains high.

Key entities

  • Person
    Eric Honroth

    New President and CEO of AngioDynamics.

  • Person
    Jim Clemmer

    Outgoing CEO, transitioning to consultant role.

Read at source← All news

Related articles

AUG 11
$ANGOMed

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

AngioDynamics (NASDAQ:ANGO) said MedTech is expected to become a majority of revenue by fiscal 2027, citing Auryon share gains and ongoing AMBITION BTK enrollment. Management expects no Auryon study data in fiscal 2027, discussed possible coronary use, and guided fiscal 2027 gross margin to 54% to 55% and adjusted EBITDA to $13M to $16M.

yahoo.com4 min
JUL 21
$ANGOMed

AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics (ANGO) held its fiscal 2026 Q4 and full-year earnings call. The company said full-year Med Tech growth was over 18% and reported Q4 revenue up 8% to $86.6 million. Q4 Med Tech revenue was $41.8 million (+16.7%). Auryon revenue was $17.8 million (+14.4%). Mechanical thrombectomy revenue was $11.1 million (-1.1%), with AlphaVac up 38.4% and AngioVac down 15.8%. Catalysts include IDE approvals for AlphaReturn and an AngioVac study.

yahoo.com7 min
JUL 14
$ANGOMed

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year…

ANGIODYNAMICS INC (ANGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20077916_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability Delivered its seventh consecutive quarter of double-digit

SEC EDGAR 8-K6 min